163 related articles for article (PubMed ID: 34507678)
1. Two cases of polycystic ovary syndrome with onset of severe ovarian hyperstimulation syndrome following controlled ovarian stimulation with aromatase inhibitors for fertility preservation before breast cancer treatment.
Oishi S; Mekaru K; Nakamura R; Miyagi M; Akamine K; Heshiki C; Aoki Y
Taiwan J Obstet Gynecol; 2021 Sep; 60(5):931-934. PubMed ID: 34507678
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors for subfertile women with polycystic ovary syndrome.
Franik S; Kremer JA; Nelen WL; Farquhar C
Cochrane Database Syst Rev; 2014 Feb; (2):CD010287. PubMed ID: 24563180
[TBL] [Abstract][Full Text] [Related]
3. WITHDRAWN: Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome.
Hughes E; Collins J; Vandekerckhove P
Cochrane Database Syst Rev; 1996 Apr; (1):CD000087. PubMed ID: 17636586
[TBL] [Abstract][Full Text] [Related]
4. Maximize the safety and efficacy of fertility preservation by random start/dual ovarian stimulation for early breast cancer patients.
Young SR; Chang YE; Yang WV; Lu BJ; Chou SY; Chen CH
Taiwan J Obstet Gynecol; 2023 Mar; 62(2):330-333. PubMed ID: 36965903
[TBL] [Abstract][Full Text] [Related]
5. Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome.
Casper RF; Mitwally MF
Clin Obstet Gynecol; 2011 Dec; 54(4):685-95. PubMed ID: 22031258
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
7. The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study.
Tshzmachyan R; Hambartsoumian E
J Gynecol Obstet Hum Reprod; 2020 Feb; 49(2):101643. PubMed ID: 31563697
[TBL] [Abstract][Full Text] [Related]
8. Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer.
Reddy J; Oktay K
Fertil Steril; 2012 Dec; 98(6):1363-9. PubMed ID: 23058686
[TBL] [Abstract][Full Text] [Related]
9. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
Xiao ZN; Peng JL; Yang J; Xu WM
Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
[TBL] [Abstract][Full Text] [Related]
10. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
11. Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: a retrospective case series.
Yacoub S; Cadesky K; Casper RF
J Ovarian Res; 2021 Feb; 14(1):31. PubMed ID: 33579321
[TBL] [Abstract][Full Text] [Related]
12. Effect of the oral contraceptive pill on patients undergoing controlled ovarian hyperstimulation.
Frederick J; DaCosta V; Wynter S; Reid M; Frederick C; McKenzie C
West Indian Med J; 2004 Jan; 53(1):39-43. PubMed ID: 15114893
[TBL] [Abstract][Full Text] [Related]
13. Persistent megalocystic ovary following in vitro fertilization in a postpartum patient with polycystic ovarian syndrome.
Ling SY; Chong KM; Hwang JL
Taiwan J Obstet Gynecol; 2006 Mar; 45(1):70-2. PubMed ID: 17272214
[TBL] [Abstract][Full Text] [Related]
14. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis.
Griesinger G; Diedrich K; Tarlatzis BC; Kolibianakis EM
Reprod Biomed Online; 2006 Nov; 13(5):628-38. PubMed ID: 17169171
[TBL] [Abstract][Full Text] [Related]
15. Severe ovarian hyperstimulation syndrome (OHSS) and icterus.
Nawroth F; Heinrich J; Bruns U; Wood WG
Hum Reprod; 1996 Nov; 11(11):2441-2. PubMed ID: 8981129
[TBL] [Abstract][Full Text] [Related]
16. Serum albumin levels in women with ovarian hyperstimulation syndrome with or without polycystic ovaries.
Alserri A; Holzer H; Tulandi T
J Obstet Gynaecol Can; 2012 Sep; 34(9):866-869. PubMed ID: 22971456
[TBL] [Abstract][Full Text] [Related]
17. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH.
Tarlatzis BC; Griesinger G; Leader A; Rombauts L; Ijzerman-Boon PC; Mannaerts BM
Reprod Biomed Online; 2012 Apr; 24(4):410-9. PubMed ID: 22386594
[TBL] [Abstract][Full Text] [Related]
18. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
[TBL] [Abstract][Full Text] [Related]
19. [A relation between the polycystic ovary syndrome and the status of ovarian hyperstimulation syndrome in IVF patients after controlled hyperstimulation].
Moosová M; Moos J; Filová V; Pavelková J; Jarosová R; Rezábek K
Ceska Gynekol; 2011 Apr; 76(2):123-7. PubMed ID: 21649996
[TBL] [Abstract][Full Text] [Related]
20. In vitro maturation.
Walls ML; Hart RJ
Best Pract Res Clin Obstet Gynaecol; 2018 Nov; 53():60-72. PubMed ID: 30056110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
